- Home
- AMRN vs FLC Comparison
AMRN vs FLC Comparison
Compare AMRN & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.70
Company Overview
Basic Information| Metric | AMRN | FLC |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 181.5M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMRN | FLC |
|---|---|---|
| Price | $13.70 | $17.34 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 87.2K | 37.8K |
| Earning Date | 10-29-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.64% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $12.62 |
| 52 Week High | $20.90 | $15.45 |
Technical Indicators
Market Signals| Indicator | AMRN | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 32.49 | 46.45 |
| Support Level | $13.41 | $17.25 |
| Resistance Level | $14.30 | $17.68 |
| Average True Range (ATR) | 0.72 | 0.14 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 8.95 | 24.44 |
Price Performance
Historical Comparison AMRN
FLC
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.